^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TheraSphere (yttrium 90 microspheres)

    Associations

    News

    Trials
    Company:
    Boston Scientific
    Drug class:
    Beta radiation emitter
    Related drugs:
    Associations

    News

    Trials
    5d
    Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=30, Recruiting, University of Miami | Trial completion date: May 2031 --> Aug 2031 | Trial primary completion date: May 2031 --> Aug 2031
    Trial completion date • Trial primary completion date
    |
    Stivarga (regorafenib) • TheraSphere (yttrium 90 microspheres)
    1m
    INDIGO: TheraSphere Japan Pre-Market Study (clinicaltrials.gov)
    P=N/A, N=51, Recruiting, Boston Scientific Corporation | Trial completion date: Apr 2027 --> Dec 2027 | Trial primary completion date: Mar 2027 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    TheraSphere (yttrium 90 microspheres)
    1m
    Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=30, Recruiting, University of Miami | Trial completion date: Jan 2031 --> May 2031 | Trial primary completion date: Jan 2031 --> May 2031
    Trial completion date • Trial primary completion date
    |
    Stivarga (regorafenib) • TheraSphere (yttrium 90 microspheres)
    2ms
    EMERALD-Y90: A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (clinicaltrials.gov)
    P2, N=58, Active, not recruiting, AstraZeneca | Trial completion date: Jan 2027 --> Jul 2026 | Trial primary completion date: Oct 2026 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • TheraSphere (yttrium 90 microspheres)
    2ms
    ReLIVE: Affordable Made-in-India Microspheres for Liver Cancer Therapy (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Post Graduate Institute of Medical Education and Research, Chandigarh
    New P1 trial
    |
    TheraSphere (yttrium 90 microspheres)
    3ms
    INDIGO: TheraSphere Japan Pre-Market Study (clinicaltrials.gov)
    P=N/A, N=51, Recruiting, Boston Scientific Corporation
    New trial
    |
    TheraSphere (yttrium 90 microspheres)
    3ms
    FRONTIER: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (clinicaltrials.gov)
    P1, N=36, Recruiting, Boston Scientific Corporation | Trial completion date: Jun 2026 --> Jan 2027 | Trial primary completion date: Mar 2026 --> Jul 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    TheraSphere (yttrium 90 microspheres)
    3ms
    Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma (clinicaltrials.gov)
    P=N/A, N=64, Not yet recruiting, University of California, San Francisco | Trial completion date: May 2028 --> Dec 2028 | Initiation date: Nov 2025 --> May 2026 | Trial primary completion date: May 2028 --> Dec 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    TheraSphere (yttrium 90 microspheres)
    4ms
    EMERALD-Y90: A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (clinicaltrials.gov)
    P2, N=56, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • TheraSphere (yttrium 90 microspheres)
    4ms
    ArTisaN: TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets (clinicaltrials.gov)
    P2, N=24, Completed, Imperial College London | Recruiting --> Completed
    Trial completion
    |
    TheraSphere (yttrium 90 microspheres)
    6ms
    EMERALD-Y90: A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (clinicaltrials.gov)
    P2, N=60, Recruiting, AstraZeneca | N=100 --> 60
    Enrollment change
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • TheraSphere (yttrium 90 microspheres)
    7ms
    Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk (clinicaltrials.gov)
    P2, N=84, Suspended, Northwestern University | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial primary completion date
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • TheraSphere (yttrium 90 microspheres)